Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1202

Girentuximab

Home » Girentuximab

Background of Girentuximab

Girentuximab is a humanized monoclonal antibody that specifically targets CAIX, a protein highly expressed in renal cell carcinoma but expressed at low levels in normal tissues. By binding to CAIX, Girentuximab can recognize and attack tumor cells, inhibiting their growth and spread. The mechanism of action of Girentuximab primarily involves direct inhibition of tumor cell proliferation and induction of immune responses. It can block tumor cell growth signaling by binding to CAIX and induce cell apoptosis. In addition, Girentuximab can activate the immune system, promoting immune clearance of tumor cells.

Specifications

Catalog Number:
KB-1202
Antibody Name:
Girentuximab
Isotype:
Human IgG1,kappa
FC Muations:
Wild Type
Target:
CAIX
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Constantijn H J ,Muselaers, Alexander B ,et al.Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.[J].Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.DOI:10.2967/jnumed.114.137356.
  2. Divgi C R , Uzzo R G , Gatsonis C ,et al.Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial[J].Journal of Clinical Oncology, 2013.DOI:10.1200/jco.2011.41.2445.